Genome-wide Studies Reveal Genetic Risk Factors for Hepatic Fat Content.


Journal

Genomics, proteomics & bioinformatics
ISSN: 2210-3244
Titre abrégé: Genomics Proteomics Bioinformatics
Pays: England
ID NLM: 101197608

Informations de publication

Date de publication:
03 Jul 2024
Historique:
received: 02 11 2022
revised: 12 11 2023
accepted: 08 01 2024
medline: 15 8 2024
pubmed: 15 8 2024
entrez: 14 8 2024
Statut: ppublish

Résumé

Genetic susceptibility to metabolic associated fatty liver disease (MAFLD) is complex and poorly characterized. Accurate characterization of the genetic background of hepatic fat content would provide insights into disease etiology and causality of risk factors. We performed genome-wide association study (GWAS) on two noninvasive definitions of hepatic fat content: magnetic resonance imaging proton density fat fraction (MRI-PDFF) in 16,050 participants and fatty liver index (FLI) in 388,701 participants from the United Kingdom (UK) Biobank (UKBB). Heritability, genetic overlap, and similarity between hepatic fat content phenotypes were analyzed, and replicated in 10,398 participants from the University Medical Center Groningen (UMCG) Genetics Lifelines Initiative (UGLI). Meta-analysis of GWASs of MRI-PDFF in UKBB revealed five statistically significant loci, including two novel genomic loci harboring CREB3L1 (rs72910057-T, P = 5.40E-09) and GCM1 (rs1491489378-T, P = 3.16E-09), respectively, as well as three previously reported loci: PNPLA3, TM6SF2, and APOE. GWAS of FLI in UKBB identified 196 genome-wide significant loci, of which 49 were replicated in UGLI, with top signals in ZPR1 (P = 3.35E-13) and FTO (P = 2.11E-09). Statistically significant genetic correlation (rg) between MRI-PDFF (UKBB) and FLI (UGLI) GWAS results was found (rg = 0.5276, P = 1.45E-03). Novel MRI-PDFF genetic signals (CREB3L1 and GCM1) were replicated in the FLI GWAS. We identified two novel genes for MRI-PDFF and 49 replicable loci for FLI. Despite a difference in hepatic fat content assessment between MRI-PDFF and FLI, a substantial similar genetic architecture was found. FLI is identified as an easy and reliable approach to study hepatic fat content at the population level.

Identifiants

pubmed: 39142818
pii: 7649324
doi: 10.1093/gpbjnl/qzae031
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

Raul Aguirre-Gamboa (R)
Patrick Deelen (P)
Lude Franke (L)
Jan A Kuivenhoven (JA)
Esteban A Lopera-Maya (EA)
Ilja M Nolte (IM)
Serena Sanna (S)
Harold Snieder (H)
Morris A Swertz (MA)
Peter M Visscher (PM)
Judith M Vonk (JM)
Cisca Wijmenga (C)

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press and Science Press on behalf of the Beijing Institute of Genomics, Chinese Academy of Sciences / China National Center for Bioinformation and Genetics Society of China.

Auteurs

Yanni Li (Y)

Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.
Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin 300052, China.

Eline H van den Berg (EH)

Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.

Alexander Kurilshikov (A)

Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.

Dasha V Zhernakova (DV)

Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.
Laboratory of Genomic Diversity, Center for Computer Technologies, ITMO University, Saint Petersburg 199034, Russia.

Ranko Gacesa (R)

Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.
Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.

Shixian Hu (S)

Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.
Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.
Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.

Esteban A Lopera-Maya (EA)

Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.

Alexandra Zhernakova (A)

Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.

Vincent E de Meijer (VE)

Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.

Serena Sanna (S)

Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.

Robin P F Dullaart (RPF)

Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.

Hans Blokzijl (H)

Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.

Eleonora A M Festen (EAM)

Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.

Jingyuan Fu (J)

Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.
Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.

Rinse K Weersma (RK)

Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH